Study type

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Disease epidemiology
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Registry-based longitudinal cohort study
Study drug and medical condition

Medical condition to be studied

Asthma
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

11000
Study design details

Main study objective

To describe the ISAR cohort who initiate biologic treatment and examine clinical outcomes at 12 months by biologic class, and subgroups of patients, and compare these to those not initiated on biologic medications

Outcomes

Asthma exacerbations, asthma control, oral corticosteroid use and dose, healthcare utilisation, lung function, Inflammatory markers, asthma symptoms, lung function

Data analysis plan

Overall and by subset groups (type of biologics, individual biologics, and baseline characteristics), descriptive statistics for Section 5.1 Demographic Variables (Table 2) and Section 5.2 Clinical Variables (Table 3) will be provided for continuous and categorical variables accordingly: Descriptive statistics for the overall population and by subgroup of interest: •For variables measured on the interval or ratio scale, summary statistics produced will be: Sample size (n), Percentage nonmissing, Mean, Standard deviation, Range (minimum-maximum), Median •Inter-quantile range (25th and 75th percentile) •For categorical variable the summary statistics will include: Sample size (n) •Range (if applicable) •Count and percentage by category (distribution) •Characteristics of study groups will be compared and tested for statistical significance via McNemar’s tests for comparison of counts data, t-test, or one-way analysis of variance (ANOVA) for continuous variables.